drugset / Trial / NCT01158729

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

NCT01158729

RandomizedParallel-groupDouble-blindPrevention

Summary

A prospective, randomized, placebo-controlled, double-blinded pilot study is planned. Neonates undergoing surgeries requiring cardiopulmonary bypass will receive antithrombin III (ATIII) supplementation or placebo in addition to standard anticoagulation with heparin as currently practiced at Children's Hospital of Wisconsin. We plan to enroll the first 60 sequential patients meeting criteria who consent to inclusion. The primary outcomes will be rates of adverse events to monitor safety. Secondary outcomes include volume of postoperative blood loss and packed red blood cell transfusion during the first 24 postoperative hours, and ATIII levels during and after bypass to determine pharmacokinetics.

Timeline

Start
2011-08
Primary completion
2013-12
Completion
2013-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject KW-3357 Protein / enzyme biologic Intravenous

Indications

No indication recorded.